Table 1.
Survival outcomes based on absolute lymphocyte count recovery after autologous hematopoietic stem cell transplantation.
| Study [reference] | Study design (disease) |
Days after AHSCT ALC obtained | ALC cut-off value (µ/L) | OS | PFS | ||||
|---|---|---|---|---|---|---|---|---|---|
| yrs | rates | P | yrs | rates | P | ||||
| Porrata et al., 2001 [5] | Retrospective | <0.0001 | <0.0001 | ||||||
| (non-Hodgkin's lymphoma) | 15 | ≥500 | 5 | 85% | 5 | 72% | |||
| <500 | 5 | 15% | 5 | 0% | |||||
| Retrospective | <0.0001 | <0.0003 | |||||||
| (multiple myeloma) | 15 | ≥500 | 5 | 30% | 5 | 20% | |||
| <500 | 5 | 0% | 5 | 0% | |||||
|
| |||||||||
| Porrata et al., 2001 [13] | Retrospective | <0.0001 | <0.0001 | ||||||
| (metastatic breast cancer) | 15 | ≥500 | 3 | 55% | 3 | 45% | |||
| <500 | 3 | 0% | 3 | 0% | |||||
|
| |||||||||
| Porrata et al., 2002 [14] | Retrospective | <0.0001 | <0.002 | ||||||
| (Hodgkin's lymphoma) | 15 | ≥500 | 5 | 80% | 5 | 50% | |||
| <500 | 5 | 30% | 5 | 20% | |||||
|
| |||||||||
| Porrata et al., 2002 [15] | Retrospective | <0.0009 | <0.0008 | ||||||
| (acute myelogenous leukemia) | 15 | ≥500 | 5 | 68% | 5 | 66% | |||
| <500 | 5 | 19% | 5 | 5% | |||||
|
| |||||||||
| Ferrandina et al., 2003 [16] | Retrospective | <0.0015 | <0.0026 | ||||||
| (ovarian cancer) | 365 | ≥850∗ | 3 | 93% | 3 | 86% | |||
| <850 | 3 | 62% | 3 | 23% | |||||
|
| |||||||||
| Gordan et al., 2003 [17] | Retrospective | 0.27 | <0.02 | ||||||
| (Hodgkin's and non-Hodgkin's lymphoma) | 15 | ≥667 | 5 | 70% | 5 | 55% | |||
| <667 | 5 | 60% | 5 | 25% | |||||
|
| |||||||||
| Nieto et al., 2004 [18] | Retrospective | <0.04 | <0.007 | ||||||
| (metastatic breast cancer) | 15 | ≥500 | 5 | 42% | 5 | 58% | |||
| <500 | 5 | 29% | 5 | 18% | |||||
|
| |||||||||
| Kim et al., 2004 [19] | Retrospective | <0.005 | <0.011 | ||||||
| (T-cell non-Hodgkin's lymphoma) | 25 | ≥1000 | 5 | 48% | 5 | 80% | |||
| <1000 | 5 | 18% | 5 | 30% | |||||
|
| |||||||||
| Porrata et al., 2005 [20] | Retrospective | <0.0003 | <0.0001 | ||||||
| (systemic amyloidosis) | 15 | ≥500 | 5 | 95% | 5 | 80% | |||
| <500 | 5 | 40% | 5 | 30% | |||||
|
| |||||||||
| Kim et al., 2006 [21] | Retrospective | <0.0156 | <0.0243 | ||||||
| (multiple myeloma) | 23 | ≥1000 | 5 | 50% | 5 | 35% | |||
| <1000 | 5 | 27% | 5 | 10% | |||||
|
| |||||||||
| Boulassel et al., 2006 [22] | Retrospective | <0.001 | <0.001 | ||||||
| (Lymphoproliferative disorders) | 15 | ≥500 | 3 | 91% | 5 | 70% | |||
| <500 | 3 | 68% | 5 | 20% | |||||
|
| |||||||||
| Joao et al., 2006 [23] | Retrospective | <0.01 | <0.0006 | ||||||
| (mantle cell lymphoma) | 15 | ≥500 | 5 | 70% | 5 | 70% | |||
| <500 | 5 | 25% | 5 | 5% | |||||
|
| |||||||||
| Porrata et al., 2008 [6] | Prospective | <0.0001 | <0.0001 | ||||||
| (non-Hodgkin's lymphoma) | 15 | ≥500 | 5 | 80% | 5 | 63% | |||
| <500 | 5 | 37% | 5 | 13% | |||||
|
| |||||||||
| Valtola et al., 2016 [7] | Prospective | <0.002 | <0.015 | ||||||
| (non-Hodgkin's lymphoma) | 15 | ≥500 | 3 | 88% | 3 | 80% | |||
| <500 | 3 | 30% | 3 | 38% | |||||
∗This number is based on the CD3 count. ALC: absolute lymphocyte count; AHSCT: autologous hematopoietic stem cell transplantation; yrs: years.